symbol: MTLF
Cycle B.N.:
True to:

Company profile

Matricelf is a pioneering biotechnology company developing a platform for autologous matrix and cells implants for a wide range of medical conditions. The company was established in 2019 by Professor Tal Dvir of the Laboratory for Tissue Engineering and Regenerative Medicine from Tel Aviv University. Our patented technology is a product of eight years of research and $12 million in grants.

Download Materials

Investor Deck 2023 - En
Investor Deck 2023 - Heb
דוח תקופתי לשנת מונגש 2022
2022 H1 Financial Report
Investor Presentation - Heb
Investor Presentation - En
Matricelf 2021 financial report

Press Release

Matricelf completed successfully the production of mature human neural tissue implants!!!
January 18, 2023


H.C. Wainwright & Co., LLC BioConnect Conference.
January 11, 2022
BIO CEO & Investor conference.
February 10, 2020
Global Startup Competition.
January 7, 2020
ICI 2019.
December 9, 2019
Seed Award.
August 27, 2019